Absolutely agree. For me, this is the most important technical issue for us. The inhibition of NGF is an one part of the puzzle understood but the other one is around cartilage regeneration/repair. How does that work? If we really understood these and were able to screen patients for efficacy based on tests derived from this understanding then our FDA pathway would be very smooth.
Ann: Paradigm to present at NWR Virtual Conference, page-34
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
0.005(2.13%) |
Mkt cap ! $82.20M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 24.5¢ | 23.0¢ | $37.41K | 157.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 4506 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.5¢ | 34937 | 7 |
View Market Depth
| Last trade - 13.37pm 10/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |